Abstract Previous studies have shown that dexa-subsequent to the binding of PTH and PTHrP to a methasone enhanced the expression of parathyroid-specific membrane-associated receptor [7] . The cDNA hormone/parathyroid-hormone-related peptide (PTH/ of this receptor has been cloned in rat osteoblast-like PTHrP) receptor mRNA in ROS 17/2.8 osteosarcoma cells (ROS 17/2.8), opossum renal epithelial cells [4, 8] , cells. The aim of this study was to determine whether and human bone and kidney [9] . This receptor binds the induction of PTH/PTHrP receptor expression PTH and PTHrP indistinguishably [10] . In contrast, a in such osteoblast-like cells is regulated at the gene recent study identified another receptor that binds level. Dexamethasone increased the steady-state levels exclusively PTH, and which appears to be relatively of PTH/PTHrP receptor mRNA twofold at 6 h, tissue specific [11] . The expression of the PTH/PTHrP and nearly threefold at 24 h. The half-life of the receptor in osteoblastic cell lines is one of the criteria PTH/PTHrP receptor mRNA, in the presence of of osteoblastic phenotype [12] . It is modulated by actinomycin D, was 6 h both in untreated and in several factors, including 1,25 dihydroxyvitamin D dexamethasone-treated cells. When measured by nuc-[13], retinoic acid [14] , and cytokines or growth factors lear run-on assay, the rate of PTH/PTHrP receptor [14] [15] [16] . gene transcription was increased twofold at 24 h.
Introduction
. The mechanisms of action of glucocorticoids on the osteoblast remain incompletely understood. The The actions of PTH and PTHrP on classical targets available evidence has stimulated us to explore the such as bone and kidney, and on various other tissues underlying molecular basis for the regulatory effect of such as chondrocytes [1] , fibroblasts [2] , and lymphoglucocorticoids on PTH/PTHrP receptor expression in cytes [3] involve the activation of several intracellular the clonal osteoblast-like cell, ROS 17/2.8. The present second messengers including cAMP, calcium, and study has been designed to explore our hypothesis that phosphoinositol trisphosphate [4] [5] [6] . Such actions are the upregulation of PTH/PTHrP receptor expression in ROS 17/2.8 osteoblastic cells by dexamethasone
Materials and methods Total RNA isolation and Northern analysis
Aliquots of equal amounts of extracted RNA (20 mg) were Materials denatured and separated by electrophoresis in 1% agarose-2.2 M formaldehyde gel, and blotted onto nitrocelluDulbecco's modified Eagle's medium, penicillin, streptomycin, and restriction endonuclease were purchased from Gibco lose membranes. Hybridization was performed using randomly primed [a-32P] deoxy-CTP-labelled cDNA probes (Grand Island, NY ). Synthetic rat (r) PTH , and (Tyr 36) chicken (c) PTHrP (1-36) NH2 were purchased from of rat PTH/PTHrP receptor (1.8 kb). Denatured probe (1×106 c.p.m./ml ) was added directly to the prehybridization Bachem, Inc. (Torrance, CA) and Peninsula Laboratories (Belmont, CA) respectively. Ham's F-12, dexamethasone, mix and incubated overnight at 42°C. Membranes were washed three times in 1×SSC-0.1% SDS at 24°C for 30 min cycloheximide, actinomycin D, progesterone, and fetal bovine serum were obtained from Sigma (St Louis, MO), and Hybri-each time, followed by a final wash with the same solution at 65°C for 30 min. The membranes were then exposed to slot Manifold apparatus from Gibco. Glucocorticoid receptor antagonist, RU 38 486, was kindly provided by Roussel-Uclaf an X-ray Kodak film with an intensifying screen at −80°C.
For reprobing, the blots were washed in boiling 0.01% SDS (Romainville, France), and rPTH/PTHrP cDNA (R15B) was a generous gift from G. V. Segre MD, Endocrine Unit, for 30 min. Hybridization signals on the blots were analysed quantitatively by densitometric scanning of autoradiograms Harvard Medical School, Boston, MA.
after various exposure times.
Nuclear run-on assays

Methods
Nuclear run-on assays were performed as described previously with minor modifications [25] . Cells were treated for
Cell culture 24 h either with 1 mM dexamethasone or vehicle and washed with phosphate-buffered saline (PBS ). Nuclei were isolated Rat osteoblast-like osteosarcoma cells (ROS 17/2.8) were by brief treatment of the cells in ice-cold lysis buffer (10 mM cultured in Ham's F-12: Dulbecco's modified Eagle's medium Tris hydrochloride (pH 7.4), 10 mM NaCl, 3 mM MgCl 2 , (151) containing 100 U/ml penicillin, 100 mg/ml streptomy-0.5% Nonidet P-40). Nuclei were suspended in 100 ml of cin, and 5% heat-inactivated fetal bovine serum. The cells glycerol buffer (50 mM Tris hydrochloride (pH 8.3), 40% were incubated in a humidified atmosphere containing 95% (vol5vol ) glycerol, 5 mM MgCl 2 , 0.1 mM EDTA). An equal air and 5% CO 2 at 37°C. Media were replaced every 3 days, volume of reaction buffer (10 mM Tris hydrochloride (pH 8), and the cells were passaged by trypsination when they became 5 mM MgCl 2 , 100 mM KCl, 2 mM CTP, 2 mM GTP, 2 mM nearly confluent. For glucocorticoid treatments, dexametha-ATP, 5 mM dithiothreitol ) was added to the nuclei suspensone in absolute ethanol was added to culture medium to a sion and incubated at 30°C for 30 min with 100 mCi of final concentration of 1 mM. Glucocorticoid receptor antag-[a32-P]-UTP (>3000 Ci/mmol ). Transcription was terminonists, RU 38 486 and progesterone were dissolved in sterile ated by addition of 40 U of DNase I, 10 mM Tris hydroabsolute ethanol, and cells were treated with 1 mM dexa-chloride (pH 7.4), 100 mM NaCl, 1 mM EDTA, 60 mg of methasone with or without 1 pM RU 38 486, or 1 mM yeast tRNA per ml, 150 U of RNasin per ml for 15 min at progesterone for 24 h. Control cells received the same concen-37°C. Proteinase K (750 mg/ml ) and 1% SDS were then tration of ethanol.
added for 30 min at 37°C. Nuclear RNA was isolated by phenol-chloroform extractions and then ethanol precipitated three times in 2.5 M ammonium acetate. Equal numbers of counts (107 c.p.m. per reaction) from dexamethasone-treated
Binding assays
and control ROS 17/2.8 cells were hybridized to cDNA. Denatured cDNA was blotted directly per well on nitrocellu-PTH binding was measured using 2×105 c.p.m./ml 125I-lose paper by using a Manifold apparatus, and included the labelled cPTH-related protein (PTHrP) (1-36) as the labelled rat bone receptor (R15B) cDNA, the human b-actin cDNA, ligand and rPTH (1-34) as the unlabelled ligand. cPTHrP the 30-base-pair oligonucleotide (5∞-GGG TGG AGG CCG (1-36) NH2 was iodinated to specific activity 1446 Ci/mmol CCG CGA GTG GAG ATC TTG-3∞) complementary to the using chloramine-T method, and the sample was injected 28S ribosomal RNA (rRNA), the glyceraldehyde3-phosphate into the high-performance liquid chromatograph using a C18 dehydrogenase (GAPDH ) cDNA (1 mg each), and PBR322 column and an elution gradient of 30-50% acetonitrile in vector (2 mg). After the hybridization the membranes were 0.1% trifluoracetic acid (TFA), as described previously [7] .
washed with several changes, 2×SSC (1.15 M NaCl, ROS 17/2.8 cells were plated in 24-well dishes at a density 0.0125 M Na citrate (pH 7.4)) for 2 h at 65°C and incubated of 5×104 cells/cm2 in which treatment with hormone at 37°C in 2×SSC with 10 mg/ml RNase for 30 min. The or vehicle was started 1 day later. Binding assays for membranes were then washed again in 2×SSC at 37°C for 125I-cPTHrP (1-36) were done directly on culture dishes. 1 h, air dried, and exposed to Kodak X-ray film at −80°C. Confluent cell monolayers were incubated with 125I-cPTHrP (1-36) (2×105 c.p.m./ml ) in binding buffer at 16°C for 4 h, with or without unlabelled rPTH (1-34). The incubation was Results terminated by removing incubation media, and cell layers were washed three times with ice-cold buffer. Cells were then solubilized with 500 ml 1 M NaOH to each well and the well Effects of dexamethasone on the steady-state level of rinsed with 2×250 ml 1 M NaOH. Radioactivity in the lysate PTH/PTHrP receptor mRNA was measured in a c-counter. Specific binding was calculated To examine whether the increase in the steady-state levels of PTH/PTHrP receptor mRNA was due to an activation of gene transcription, we performed Effects of actinomycin D and cycloheximide on nuclear run-on assays. ROS 17/2.8 cells were cul-PTH/PTHrP receptor mRNA tured in the presence or absence of dexamethasone 1 mM for 24 h, and their nuclei were isolated. One possible mechanism through which the steadyTranscription-elongation was allowed to continue in state receptor mRNA levels might be upregulated by the presence of [a32-P]-UTP and unlabelled nucleotides. dexamethasone was evaluated by examining the halfAfter elongation, radiolabelled RNA was hybridized life of PTH/PTHrP receptor mRNA. After a 24-h to cDNA. The hybridization of labelled nuclear RNA incubation with 1 mM dexamethasone, the potent to vector PBR322 DNA served as negative control inhibitor of RNA synthesis, actinomycin D, was added ( Figure 4) . b-Actin cDNA, GAPDH cDNA, and 28S (10 mg/mI final concentration), and the cells were rRNA were used as positive controls. Although the harvested at 0, 1, 2, 4, 6, 8, and 24 h after the addition rates of b-actin, GAPDH and 28S rRNA gene tranof actinomycin D. As shown in Figure 2 , although scription were essentially unchanged by treatment, the PTH/PTHrP receptor transcripts were more abundant rate of PTH/PTHrP receptor gene transcription was in the cells treated with dexamethasone for 24 h than increased twofold. Thus, dexamethasone stimulated in the untreated cells, the rate at which hormone-PTH/PTHrP receptor gene transcription at 24 h. treated mRNA decayed was unchanged relative to the untreated control cells. This indicates that dexamethasone did not alter the half-life of receptor message. We Protein synthesis inhibition estimated the half-life of receptor mRNA to be approximately 6 h. PTH/PTHrP receptor mRNA was To determine whether the previously reported increase in PTH/PTHrP binding to the receptor produced by expressed as the ratio of PTH/PTHrP receptor mRNA to 28S rRNA. The addition of cycloheximide (5 mg/ml dexamethasone treatment required de novo protein synthesis, ROS 17/2.8 cells were first incubated with final concentration), an inhibitor of protein synthesis, alone to the incubation medium led to a partial block cycloheximide (5 mg/ml ) alone ( Figure 5 ). This treatment induced a decrease in PTH-specific binding to of PTH/PTHrP receptor mRNA expression at 6 h, with a complete block being observed at 24 h 58±10% at 6 h and 40±14% at 24 h, compared with control values. The addition of cycloheximide ( Figure 3) . The simultaneous addition of cycloheximide (5 mg/ml ) and dexamethasone (1 mM ) induced a (5 mg/ml ) together with dexamethasone (1 mM ) did not change the decrease in PTH binding (63±14% minimal increase in PTH/PTHrP receptor mRNA levels. This finding indicates that the effect of dexa-and 49±10% at 6 and 24 h respectively), compared with that in cells treated with cycloheximide alone, binding, we studied the effects of progesterone, a steroid that binds to glucocorticoid receptors and indicating that the dexamethasone-induced enhanced functions as an antagonist [26 ] , and of RU 38 486, a PTH/PTHrP binding was blocked in cells exposed to glucocorticoid receptor antagonist. As shown in cycloheximide. Figure 6 , both progesterone and RU 38 486 diminished the effect of dexamethasone on PTH/PTHrP receptor Receptor dependence of glucocorticoid effects binding (56±13% and 64.1±3% in cells treated with To examine the glucocorticoid receptor dependence of progesterone and RU 38 486 respectively, and 56.6±21.3% and 62.5±15.6% in cells treated with a the effect of dexamethasone on PTH/PTHrP receptor These results were suggestive of a rapid and persistent effect of dexamethasone on ROS 17/2.8 cells combination of progesterone and dexamethasone, or via enhanced mRNA synthesis. However, depending RU 38 486 and dexamethasone respectively). Thus, on the target gene and the cells studied, glucocorticoids the effects of dexamethasone on PTH/PTHrP receptor have been shown to change either transcriptional rate, mRNA are mediated by the glucocorticoid receptor.
mRNA . We then asked PTHrP receptor number and steady-state mRNA in a dose-and time-dependent manner in ROS 17/2.8 osteo-whether de novo protein synthesis was required for the dexamethasone effect on mRNA level. Our finding blastic cells [23, 24] . It had yet to be determined which were the mechanisms underlying the increase in recep-of an inhibition of the dexamethasone-induced upregulation of PTH/PTHrP receptor mRNA by tor number induced by the hormone in this osteoblastic cell line. The present study has been designed to explore cycloheximide suggests that the glucocorticoid effect required de novo protein synthesis. We therefore our hypothesis that the upregulation of PTH/PTHrP receptor expression in ROS 17/2.8 osteoblastic cells by explored the level of transcription by nuclear run-on assay. The rate of transcription of the PTH/PTHrP dexamethasone occurs at the transcriptional level, in the absence of a change in receptor mRNA stability. receptor gene proved to be increased twofold in ROS 17/2.8 cells treated with dexamethasone for 24 h, comWe used the concentration of 1 mM dexamethasone, pared with control cells. Taken together, our observa-agreement with a previous study [24] . To our knowledge only glucocorticoids and transforming growth tions therefore suggested that the stimulatory effect of dexamethasone on PTH/PTHrP receptor mRNA factor-b1 [16 ] have been shown to increase PTH/PTHrP receptor mRNA levels in ROS 17/2.8 expression was rapid, was not due a change in mRNA stability, required de novo protein synthesis, and was cells whereas 1,25(OH ) 2 vitamin D3 and TNF-a decrease its level in clonal osteoblast-like cells [13, 14] . mainly due to an increase in the activation of PTH/PTHrP receptor gene transcription. The mechan-
In conclusion, our results show a rapid increase of PTH/PTHrP receptor expression in osteoblast-like cells ism of the increase in PTH/PTHrP receptor number in this osteoblastic cell line is similar to the one in reponse to dexamethasone, via an enhancement at the transcriptional level. reported for TRH receptor in GH4C1 cells [29] .
Using ligand-binding methods, we showed for the
